A new vaccine for swine is launched in the US

A new therapy created for protection against the most prevalent genotypes of porcine circovirus type 2 (PCV2) has been launched on the veterinary market. The porcine circovirus vaccine, type 2, killed baculovirus vector (Ingelvac Circoflex AD; Boehringer Ingelheim [BI]), is the first vaccine to combine PVC2a and PVC2d antigens in a single dose, according to BI.1

“These 2 genotypes are responsible for over 90% of clinical cases,” Gerard Ensink, global head of swine at Boehringer Ingelheim, said in a news release.1 “Our customers can count on us for continuous vaccine innovation. With Ingelvac Circoflex AD, we’re further advancing protection against evolving PCV2 threats.”

PCV2 is the cause of porcine circovirus-associated disease (PCVAD) and is one of the most common viruses in the swine production industry. PCVAD compromises the immune system of pigs and enhances coinfections, putting these animals at higher risk of respiratory, reproductive, and digestive diseases. Signs of PCVAD can include severe weight loss, trouble breathing, and diarrhea.1

In 2023, Merck Animal Health launched a ready-to-use, single-dose vaccine to protect pigs ages 3 weeks and older against disease caused by PCV2a and PCV2, as well as Mycoplasma hyopneumoniae and Lawsonia intracellularis. This product (Circumvent CML) contains a subunit vaccine based on PCV2a. It has an immunity duration of at least 16 weeks for PCV2d, and an unknown immunity duration for PCV2a.3,4

Granted a product license approval by the USDA, the PCV2 vaccine from BI is indicated for healthy pigs aged as young as 2 weeks. It is administered through an intramuscular 1-mL dose. This vaccine is available in 50-dose and 250-dose presentations.1,2

The BI vaccine’s efficacy was demonstrated through multiple studies with data submitted to the USDA. Immunity onset occurs 2 weeks post vaccination, and the duration is at least 6 months.1,2 

RELATED: 2 automatic swine syringes are introduced to the veterinary market

Steve Boren, vice president, US Livestock at BI, noted that the vaccine reflects the company’s commitment to PCV2 control and empowering producers to manage herd health. “In an industry where disease is a constant challenge, this next-generation vaccine offers broader, safer, longer-lasting immunity against the most prevalent PCV2 genotypes and can help proactively strengthen a herd’s immune system,” Boren said in a news release.1

PCV2d has become a predominant genotype in the US and around the world, according to BI. “We’ll continue to closely monitor PCV2 and other diseases impacting pig performance to help producers stay ahead of emerging risks,” Ensink said.1

References

1. Boehringer Ingelheim launches swine vaccine with advanced protection against porcine circovirus type 2 in the United States. News release. Boehringer Ingelheim. September 3, 2025. Accessed September 3, 2025. https://www.boehringer-ingelheim.com/us/media/press-releases/boehringer-launches-swine-vaccine-advanced-protection-against-pcv2
2. Summary of studies supporting USDA product licensure. USDA. March 21, 2025. Accessed September 4, 2025. https://www.aphis.usda.gov/sites/default/files/2025-04/124-19k5r9.pdf
3. Novel vaccine on the market for viruses in pigs. dvm360. June 8, 2023. Accessed September 4, 2025. https://www.dvm360.com/view/novel-vaccine-on-the-market-for-viruses-in-pigs
4. Circumvent CML. Product label. Merck Animal Health. Accessed September 4, 2025. https://merckusa.cvpservice.com/product/view/1047582